A potential ‘home run’ trade is emerging in this pharma stock
I recently laid out a bullish thesis for Gilead Sciences (GILD) , and that trade just expired on Friday with a 144% gain. The bullish debit vertical spread successfully captured the upside to a new 52-week high as sentiment improved around Gilead’s strengthening HIV franchise and expanding oncology portfolio. I’m looking to roll our profits into a new bullish…